BLASINGLE-DOSEVIAL
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
KANJINTI (trastuzumab-anns) by Amgen is her2/neu/cerbb2 antagonists [moa]. Approved for her2/neu receptor antagonist [epc]. First approved in 2019.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KANJINTI (trastuzumab-anns) is a monoclonal antibody biosimilar that targets HER2/neu receptors, used to treat HER2-positive breast cancers and gastric cancers. It works by blocking HER2 signaling, inhibiting tumor cell proliferation and survival. This is a biosimilar referencing the originator trastuzumab (Herceptin).
$4MPart D
PeakKANJINTI is in peak commercial phase with modest Part D penetration; team size likely stable with focus on maintaining market position against multiple biosimilar competitors.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KANJINTI currently shows zero linked job postings, indicating limited career visibility despite peak commercial phase. Work on this product would focus on defensive market positioning, biosimilar differentiation via manufacturing/pricing, and payer strategy in a highly competitive segment.
Company
Worked on KANJINTI at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.